الفهرس 
Renal OsteodystrophyOnly 14 pages are availabe for public view
 |  | from | 167 |  |  |
| | | from | 167 | | |
Abstract
Introduction: Disturbances of bone and mineral metabolism are a hallmark of chronic kidney disease (CKD). Aim of the Work: The aim of this study is to investigate the possible effect of bisphosphonate therapy on bone specific markers in prevalent haemodialysis patients. Patients and Methods: This study is a randomized clinical trial; phase IV (double blind) of the possible effect of bisphosphonate therapy on bone specific markers in prevalent hemodialysis patients that was conducted in hemodialysis units, Ain Shams University Hospital. Results: Our study is a randomized clinical intervention trial (double blind). 23 adult prevalent hemodialysis patients from hemodialysis units in Ain-Shams university hospitals participated in the trial. Patients were divided into 2 groups: group A: patients who received Ibandronate 75mg per months (50% of usual dose) for 6 months. group B: patients who received identical placebo tablet monthly for 6 months. Summary and Conclusion: Our study is a randomized clinical intervention trial (double blind). Twenty three adult prevalent hemodialysis patients from hemodialysis units in Ain Shams university hospitals participated in the trial for evaluation of the possible effect of bisphosphonate therapy on bone specific markers in this group of patients. Patients were randomly selected from the hemodialysis units, and they were randomized to take either the drug or the placebo tablet.